Severe graves ophthalmopathy accompanied by HTLV-1-associated uveitis (HAU) and anti-neutrophil cytoplasmic antibody-related vasculitis: a case report and a review of the literature of HAU with Graves disease.
A 50-year-old woman was admitted because of severe exophthalmos associated with Graves disease. She underwent methimazole (MMI) and methylprednisolone pulse therapy against exophthalmos. She noticed photophobia and blurred vision 3 weeks after the start of pulse therapy and she was diagnosed as having uveitis. Methylprednisolone pulse therapy was performed again for both exophthalmos and uveitis, followed by daily administration of 20 mg of prednisolone and instillation of betamethasone for 2 weeks and the uveitis was improved. Western blot analysis confirmed that human T lymphotropic virus type 1 (HTLV-1) antibody was present in her serum. Propylthiouracil was substituted for MMI and HTLV-1-associated uveitis (HAU) has not recurred. Six months after the beginning of administration of PTU, anti-neutrophil cytoplasmic antibody-related vasculitis developed in the patient. We review 43 cases of HAU with Graves disease, including the present case, in the literature. Only 2 of 27 cases (except unknown cases) (7.4%) had Graves ophthalmopathy. To the best of our knowledge, there has been no investigation of HAU and Graves ophthalmopathy.
Third Department of Internal Medicine, Gifu University School of Medicine, Japan. sarui@cc.gifu-u.ac.jp
Hiroshi
H
Sarui
Akie
A
Sano
Takako
T
Maruyama
Kazuya
K
Nakashima
Noriyuki
N
Takeda
Keigo
K
Yasuda
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D013956:Antithyroid Agents / Q000008:administration & dosage; D005260:Female; D006111:Graves Disease / Q000150:complications* / Q000188:drug therapy; D015490:HTLV-I Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008279:Magnetic Resonance Imaging; D008713:Methimazole / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011441:Propylthiouracil / Q000008:administration & dosage; D012720:Severity of Illness Index; D013963:Thyroid Hormones / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome; D014605:Uveitis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology; D014657:Vasculitis / Q000150:complications* / Q000188:drug therapy / Q000276:immunology
D000893:Anti-Inflammatory Agents; D019268:Antibodies, Antineutrophil Cytoplasmic; D013956:Antithyroid Agents; D013963:Thyroid Hormones; D008713:Methimazole; D011441:Propylthiouracil; D011239:Prednisolone; D008775:Methylprednisolone